Skip to main content


Impairment of functional integrity of the vasculature is not changed in patients starting abacavir

Purpose of the study

In order to explore a possible pathogenetic mechanism of abacavir (ABC) cardiovascular toxicity, we assess the impact of beginning the drug on endothelial function via assessment of brachial artery diameter (BAD) and flow-mediated dilation (FMD).


Cross-sectional observational study that included all consecutive HIV-infected patients seen at a metabolic clinic who had BAD and FMD evaluation before and 9 months after beginning ABC as a component of a new drug regimen.

Summary of results

There were no overt metabolic, virological or antiretroviral drug-related factors associated with BAD and FMD change over time among patients starting ABC. (Figure 1)

Figure 1

FMD change over time including multipe observations.


Change in impairment of functional integrity of the vasculature is not an associated factor related with ABC use. Cardiovascular disease risk among HIV-infected HAART-experienced persons is likely governed by complex pathophysiologic and treatment factors.

Author information

Correspondence to G Guaraldi.

Rights and permissions

Reprints and Permissions

About this article


  • Cardiovascular Disease
  • Observational Study
  • Endothelial Function
  • Disease Risk
  • Drug Regimen